Vimarsana
Biggest News Aggregation in the World

Oladele Adebogun News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oladele Adebogun. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oladele Adebogun Today - Breaking & Trending Today

Investegate |Nexstim Oyj Announcements | Nexstim Oyj: Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD - Vimarsana News

Investegate |Nexstim Oyj Announcements | Nexstim Oyj: Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD

Nexstim Oyj Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD Press release, Helsinki, 16.04.2021, 12.00 pm (EEST) Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that the company’s SmartFocus® nTMS technology used at Mind Matters Psychiatry MD, US has generated positive feedback f...

Nexstim Oyj: Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT Systems to Treat MDD - Vimarsana News

Nexstim Oyj: Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT Systems to Treat MDD

(0) Press release, Helsinki, 16.04.2021, 12.00 pm (EEST) Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT Systems to Treat MDD Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that the company's SmartFocus nTMS technology used at Mind Matters Psychiatry MD, US has generated positive feedback from its use in treating patients with depression. Oladele Adebogun M.D. said, "I was initially introduced to Nexstim by the early outcomes of their registry which showed 50% remission rates in a small number of patients suffering from major ...